Posted: Wednesday, February 9, 2022
Researchers at Zhengzhou Central Hospital, China, performed a series of experiments to investigate how bladder cancer progression may be influenced specifically by LINC00958—the long intergenic non-protein coding RNA 958. Their work, published in BMC Oncology, focuses on the potential role of the LINC00958-miR-490-3p-AURKA axis in the growth of bladder cancer.
“Taken together, our findings indicate that LINC00958 aggravates cell growth and invasion but hampers apoptosis of bladder cancer cells via the miR-490-3p/AURKA axis. This may provide a new direction for the clinical treatment of bladder cancer patients,” stated Zhen et al.
The team used cancer tissues and adjacent normal cells from 34 patients with bladder cancer and selected the LINC00958-miR-490-3p-AURKA axis as the object of analysis. The authors found that LINC00958 was reduced by over 50% in si-lnc (silencing RNA-LINC00958) groups compared with blank groups of RT4 and T24 cells, indicating that LINC00958 was upregulated in bladder cancer tissues and cells.
Next, LINC00958 was found to enhance cell proliferation and invasion but suppress apoptosis of bladder cancer cells. A CCK8 assay showed cell viability levels were significantly lower in the Si-lnc group than the blank group of both RT4 and T24, and a BrdU assay showed cell proliferation levels in the Si-lnc group decreased by 50% compared with the blank groups. Meanwhile, cell invasion levels in the Si-lnc group downregulated by 80% in RT4 cells and by 50% in T24 cells compared with the blank group; the proapoptotic protein Bax increased in the Si-lnc group, whereas the antiapoptotic protein Bcl-2 decreased.
Further, the researchers demonstrated that LINC00958 sponges miR-490-3p in bladder cancer cells, facilitating the progression of bladder cancer and showed that miR-490-3p directly targets AURKA in bladder cancer cells. By using miR-490-3p to target AURKA, the researchers were able to hinder bladder cancer cell progression.
Disclosure: The study authors reported no conflicts of interest.